Klow on Juno

What it does

Klow adds KPV to the Glow stack, putting four complementary peptides in one fixed-ratio vial. KPV (the C-terminal tripeptide of α-MSH) contributes selective anti-inflammation via PepT1-mediated uptake and intracellular NF-κB inhibition; GHK-Cu contributes gene-expression and matrix remodeling; BPC-157 contributes angiogenesis and cytoprotection; TB-500 contributes actin-driven cell migration and broad cytokine modulation. The combination targets complex injuries that involve simultaneous tissue damage and significant inflammation. The guide lists all four as pH-compatible, which is the basis for the single-syringe product.

Used for

Post-surgical recovery

Dose

Starting: 500 mcg · 7 days/week (15 units of a 10/25/10/10 mg vial)
Common: 875 mcg · 7 days/week (15 units of a 10/25/10/10 mg vial)
Upper: 1,250 mcg · 7 days/week (15 units of a 10/25/10/10 mg vial)
When: EveningEvening dosing is commonly used to align the regenerative window with overnight repair, consistent with the GHK-Cu and TB-500 components.
How long: 2 months on / 1 month off
Site: subcutaneous
Food: any

Need exact volumes? Open the peptide calculator →

⚠ Caution

Active malignancy (theoretical angiogenesis/cell-migration concern — BPC-157, TB-500, GHK-Cu; KPV: GI-tract malignancy caution)
Wilson's disease and other copper-metabolism disorders (GHK-Cu)
Known copper sensitivity (GHK-Cu)
Active sepsis (avoid TB-500 — immunomodulatory)
Pregnancy and breastfeeding (no human safety data for any component)
Competitive athletes — BPC-157 and TB-500 are on the WADA prohibited list
Hypersensitivity to peptide formulations or excipients

Will it work for me?

Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.

Blood markers

Tier 2 — Human observationalhs-CRP / ESR↓· 6–12 weeksInflammation overlay — KPV + TB-500 anti-inflammatory action makes this more relevant than for the repair-only blends.

Functional & psychometric

Tier 3 — Animal / in vitroRegion-specific function score (DASH / KOOS / ODI)↑· 6–12 weeks
Tier 3 — Animal / in vitroPain scale (VAS / NPRS); fecal calprotectin when GI is the target↓· 2–8 weeksFunctional pain tracking for soft-tissue use; fecal calprotectin for gut-directed use.

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Cycling

2 months on, 1 month off.

Related peptides

What's in this blend

BPC-15710 mg/vial· 18%angiogenesis, cytoprotection
GHK-Cu25 mg/vial· 45%gene-expression modulation, collagen/elastin, antimicrobial
TB-50010 mg/vial· 18%actin sequestration, cell migration
KPV10 mg/vial· 18%selective NF-κB anti-inflammation via PepT1

Reconstitution & storage

Vial	BAC water	Concentration	Shelf life
55 mg	3 mL	500 mcg / 1.25 mg / 500 mcg / 500 mcg per 15 units (10/25/10/10 mg blend)	20 days

Standard blend vial is 10 mg BPC-157 + 25 mg GHK-Cu + 10 mg TB-500 + 10 mg KPV. Reconstitute with 3 mL BAC water for 500 mcg / 1.25 mg / 500 mcg / 500 mcg per 15 units; the vial lasts ~20 days at 15 units/day. Evening dosing is common to align with overnight repair.

Storage. Lyophilized: refrigerate, multi-year stability. Reconstituted: refrigerate 2–8 °C, use within ~20 days.

Open the peptide calculator →

Nasal delivery

Not suitable for nasal delivery. No established nasal protocol; the deep-tissue/systemic repair components require SQ delivery (KPV is also viable orally via PepT1, but not as the blend).

Reference

How it works

Four distinct pathways: KPV blocks NF-κB nuclear translocation (and downstream IL-1, TNF-α, IL-6) selectively in inflamed tissue; GHK-Cu modulates gene expression and rebuilds collagen/elastin; BPC-157 drives angiogenesis; TB-500 mobilizes cells. KPV's selectivity for inflamed tissue (PepT1 is upregulated under inflammation) distinguishes the anti-inflammatory action from broad immunosuppression. The four-way combination is mechanistic in rationale; no combination-specific RCT exists.

EvidenceTier 3 — Animal / in vitro

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Complex soft-tissue injury with significant inflammatory component

Tier 3high confidence

KPV adds targeted NF-κB anti-inflammation to the GHK-Cu/BPC-157/TB-500 repair triad. KPV has strong preclinical colitis-model evidence (Dalmasso 2008); the repair components are Tier 3. No combination RCT.

Dalmasso G et al. 2008 Sikiric P et al. 1993 Goldstein AL et al. 2012

Post-surgical recovery (repair + anti-inflammation + infection-risk reduction)

Tier 3medium confidence

Mechanistically Klow covers angiogenesis, matrix remodeling, cell migration, and inflammation control simultaneously; GHK-Cu adds antimicrobial action. Rationale is mechanistic; controlled human combination data is absent.

Dalmasso G et al. 2008 Pickart L et al. 2018

Chronic inflammatory conditions with a tissue-damage component (incl. gut/IBD-adjacent)